Cargando…
Prospective analysis of circulating metabolites and breast cancer in EPIC
BACKGROUND: Metabolomics is a promising molecular tool to identify novel etiologic pathways leading to cancer. Using a targeted approach, we prospectively investigated the associations between metabolite concentrations in plasma and breast cancer risk. METHODS: A nested case-control study was establ...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757362/ https://www.ncbi.nlm.nih.gov/pubmed/31547832 http://dx.doi.org/10.1186/s12916-019-1408-4 |
_version_ | 1783453561190875136 |
---|---|
author | His, Mathilde Viallon, Vivian Dossus, Laure Gicquiau, Audrey Achaintre, David Scalbert, Augustin Ferrari, Pietro Romieu, Isabelle Onland-Moret, N. Charlotte Weiderpass, Elisabete Dahm, Christina C. Overvad, Kim Olsen, Anja Tjønneland, Anne Fournier, Agnès Rothwell, Joseph A. Severi, Gianluca Kühn, Tilman Fortner, Renée T. Boeing, Heiner Trichopoulou, Antonia Karakatsani, Anna Martimianaki, Georgia Masala, Giovanna Sieri, Sabina Tumino, Rosario Vineis, Paolo Panico, Salvatore van Gils, Carla H. Nøst, Therese H. Sandanger, Torkjel M. Skeie, Guri Quirós, J. Ramón Agudo, Antonio Sánchez, Maria-Jose Amiano, Pilar Huerta, José María Ardanaz, Eva Schmidt, Julie A. Travis, Ruth C. Riboli, Elio Tsilidis, Konstantinos K. Christakoudi, Sofia Gunter, Marc J. Rinaldi, Sabina |
author_facet | His, Mathilde Viallon, Vivian Dossus, Laure Gicquiau, Audrey Achaintre, David Scalbert, Augustin Ferrari, Pietro Romieu, Isabelle Onland-Moret, N. Charlotte Weiderpass, Elisabete Dahm, Christina C. Overvad, Kim Olsen, Anja Tjønneland, Anne Fournier, Agnès Rothwell, Joseph A. Severi, Gianluca Kühn, Tilman Fortner, Renée T. Boeing, Heiner Trichopoulou, Antonia Karakatsani, Anna Martimianaki, Georgia Masala, Giovanna Sieri, Sabina Tumino, Rosario Vineis, Paolo Panico, Salvatore van Gils, Carla H. Nøst, Therese H. Sandanger, Torkjel M. Skeie, Guri Quirós, J. Ramón Agudo, Antonio Sánchez, Maria-Jose Amiano, Pilar Huerta, José María Ardanaz, Eva Schmidt, Julie A. Travis, Ruth C. Riboli, Elio Tsilidis, Konstantinos K. Christakoudi, Sofia Gunter, Marc J. Rinaldi, Sabina |
author_sort | His, Mathilde |
collection | PubMed |
description | BACKGROUND: Metabolomics is a promising molecular tool to identify novel etiologic pathways leading to cancer. Using a targeted approach, we prospectively investigated the associations between metabolite concentrations in plasma and breast cancer risk. METHODS: A nested case-control study was established within the European Prospective Investigation into Cancer cohort, which included 1624 first primary incident invasive breast cancer cases (with known estrogen and progesterone receptor and HER2 status) and 1624 matched controls. Metabolites (n = 127, acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose, sphingolipids) were measured by mass spectrometry in pre-diagnostic plasma samples and tested for associations with breast cancer incidence using multivariable conditional logistic regression. RESULTS: Among women not using hormones at baseline (n = 2248), and after control for multiple tests, concentrations of arginine (odds ratio [OR] per SD = 0.79, 95% confidence interval [CI] = 0.70–0.90), asparagine (OR = 0.83 (0.74–0.92)), and phosphatidylcholines (PCs) ae C36:3 (OR = 0.83 (0.76–0.90)), aa C36:3 (OR = 0.84 (0.77–0.93)), ae C34:2 (OR = 0.85 (0.78–0.94)), ae C36:2 (OR = 0.85 (0.78–0.88)), and ae C38:2 (OR = 0.84 (0.76–0.93)) were inversely associated with breast cancer risk, while the acylcarnitine C2 (OR = 1.23 (1.11–1.35)) was positively associated with disease risk. In the overall population, C2 (OR = 1.15 (1.06–1.24)) and PC ae C36:3 (OR = 0.88 (0.82–0.95)) were associated with risk of breast cancer, and these relationships did not differ by breast cancer subtype, age at diagnosis, fasting status, menopausal status, or adiposity. CONCLUSIONS: These findings point to potentially novel pathways and biomarkers of breast cancer development. Results warrant replication in other epidemiological studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12916-019-1408-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6757362 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-67573622019-09-30 Prospective analysis of circulating metabolites and breast cancer in EPIC His, Mathilde Viallon, Vivian Dossus, Laure Gicquiau, Audrey Achaintre, David Scalbert, Augustin Ferrari, Pietro Romieu, Isabelle Onland-Moret, N. Charlotte Weiderpass, Elisabete Dahm, Christina C. Overvad, Kim Olsen, Anja Tjønneland, Anne Fournier, Agnès Rothwell, Joseph A. Severi, Gianluca Kühn, Tilman Fortner, Renée T. Boeing, Heiner Trichopoulou, Antonia Karakatsani, Anna Martimianaki, Georgia Masala, Giovanna Sieri, Sabina Tumino, Rosario Vineis, Paolo Panico, Salvatore van Gils, Carla H. Nøst, Therese H. Sandanger, Torkjel M. Skeie, Guri Quirós, J. Ramón Agudo, Antonio Sánchez, Maria-Jose Amiano, Pilar Huerta, José María Ardanaz, Eva Schmidt, Julie A. Travis, Ruth C. Riboli, Elio Tsilidis, Konstantinos K. Christakoudi, Sofia Gunter, Marc J. Rinaldi, Sabina BMC Med Research Article BACKGROUND: Metabolomics is a promising molecular tool to identify novel etiologic pathways leading to cancer. Using a targeted approach, we prospectively investigated the associations between metabolite concentrations in plasma and breast cancer risk. METHODS: A nested case-control study was established within the European Prospective Investigation into Cancer cohort, which included 1624 first primary incident invasive breast cancer cases (with known estrogen and progesterone receptor and HER2 status) and 1624 matched controls. Metabolites (n = 127, acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose, sphingolipids) were measured by mass spectrometry in pre-diagnostic plasma samples and tested for associations with breast cancer incidence using multivariable conditional logistic regression. RESULTS: Among women not using hormones at baseline (n = 2248), and after control for multiple tests, concentrations of arginine (odds ratio [OR] per SD = 0.79, 95% confidence interval [CI] = 0.70–0.90), asparagine (OR = 0.83 (0.74–0.92)), and phosphatidylcholines (PCs) ae C36:3 (OR = 0.83 (0.76–0.90)), aa C36:3 (OR = 0.84 (0.77–0.93)), ae C34:2 (OR = 0.85 (0.78–0.94)), ae C36:2 (OR = 0.85 (0.78–0.88)), and ae C38:2 (OR = 0.84 (0.76–0.93)) were inversely associated with breast cancer risk, while the acylcarnitine C2 (OR = 1.23 (1.11–1.35)) was positively associated with disease risk. In the overall population, C2 (OR = 1.15 (1.06–1.24)) and PC ae C36:3 (OR = 0.88 (0.82–0.95)) were associated with risk of breast cancer, and these relationships did not differ by breast cancer subtype, age at diagnosis, fasting status, menopausal status, or adiposity. CONCLUSIONS: These findings point to potentially novel pathways and biomarkers of breast cancer development. Results warrant replication in other epidemiological studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12916-019-1408-4) contains supplementary material, which is available to authorized users. BioMed Central 2019-09-24 /pmc/articles/PMC6757362/ /pubmed/31547832 http://dx.doi.org/10.1186/s12916-019-1408-4 Text en © The Author(s). 2019 The opinions expressed in this article are those of the authors and do not necessarily reflect the views of the WHO, its Board of Directors, or the countries they represent. Open Access This article is licensed under the terms of the Creative Commons Attribution 3.0 IGO License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the WHO, provide a link to the Creative Commons licence and indicate if changes were made. The use of the WHO’s name, and the use of the WHO’s logo, shall be subject to a separate written licence agreement between the WHO and the user and is not authorized as part of this CC-IGO licence. Note that the link provided above includes additional terms and conditions of the licence. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/3.0/igo/. |
spellingShingle | Research Article His, Mathilde Viallon, Vivian Dossus, Laure Gicquiau, Audrey Achaintre, David Scalbert, Augustin Ferrari, Pietro Romieu, Isabelle Onland-Moret, N. Charlotte Weiderpass, Elisabete Dahm, Christina C. Overvad, Kim Olsen, Anja Tjønneland, Anne Fournier, Agnès Rothwell, Joseph A. Severi, Gianluca Kühn, Tilman Fortner, Renée T. Boeing, Heiner Trichopoulou, Antonia Karakatsani, Anna Martimianaki, Georgia Masala, Giovanna Sieri, Sabina Tumino, Rosario Vineis, Paolo Panico, Salvatore van Gils, Carla H. Nøst, Therese H. Sandanger, Torkjel M. Skeie, Guri Quirós, J. Ramón Agudo, Antonio Sánchez, Maria-Jose Amiano, Pilar Huerta, José María Ardanaz, Eva Schmidt, Julie A. Travis, Ruth C. Riboli, Elio Tsilidis, Konstantinos K. Christakoudi, Sofia Gunter, Marc J. Rinaldi, Sabina Prospective analysis of circulating metabolites and breast cancer in EPIC |
title | Prospective analysis of circulating metabolites and breast cancer in EPIC |
title_full | Prospective analysis of circulating metabolites and breast cancer in EPIC |
title_fullStr | Prospective analysis of circulating metabolites and breast cancer in EPIC |
title_full_unstemmed | Prospective analysis of circulating metabolites and breast cancer in EPIC |
title_short | Prospective analysis of circulating metabolites and breast cancer in EPIC |
title_sort | prospective analysis of circulating metabolites and breast cancer in epic |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757362/ https://www.ncbi.nlm.nih.gov/pubmed/31547832 http://dx.doi.org/10.1186/s12916-019-1408-4 |
work_keys_str_mv | AT hismathilde prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT viallonvivian prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT dossuslaure prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT gicquiauaudrey prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT achaintredavid prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT scalbertaugustin prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT ferraripietro prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT romieuisabelle prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT onlandmoretncharlotte prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT weiderpasselisabete prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT dahmchristinac prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT overvadkim prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT olsenanja prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT tjønnelandanne prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT fournieragnes prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT rothwelljosepha prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT severigianluca prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT kuhntilman prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT fortnerreneet prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT boeingheiner prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT trichopoulouantonia prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT karakatsanianna prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT martimianakigeorgia prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT masalagiovanna prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT sierisabina prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT tuminorosario prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT vineispaolo prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT panicosalvatore prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT vangilscarlah prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT nøstthereseh prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT sandangertorkjelm prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT skeieguri prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT quirosjramon prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT agudoantonio prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT sanchezmariajose prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT amianopilar prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT huertajosemaria prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT ardanazeva prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT schmidtjuliea prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT travisruthc prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT ribolielio prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT tsilidiskonstantinosk prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT christakoudisofia prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT guntermarcj prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic AT rinaldisabina prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic |